Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
Clin Neuropharmacol
; 40(4): 169-174, 2017.
Article
em En
| MEDLINE
| ID: mdl-28644160
ABSTRACT
Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these anti-CGRP monoclonal antibodies are in clinical trials for cluster headache prevention as well. Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Peptídeo Relacionado com Gene de Calcitonina
/
Sistemas de Liberação de Medicamentos
/
Cefaleia Histamínica
/
Transtornos de Enxaqueca
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article